ASMQ

Cipla

3-day cure, artemisinin-based combination therapies (TPP-1)

Artesunate- mefloquine

Access

-

Approved

Therapeutic indication	Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5 kg
Dosing	Once-daily for 3 days
Efficacy	28-day PCR-corrected ACPR* 96.2%
Key features	Long post-treatment protection 3-year shelf life
Challenges	Mefloquine API costs contribute to high price of finished product Only one prequalified manufacturer
Status	Registered by Cipla in 10 countries Prequalified in 2012 >1.3 million treatments distributed since 2012 Key role in areas of drug resistance containment in Greater Mekong Sub-region
Previously	Developed by FACT Consortium (led by DNDi and TDR) with Farmanguinhos and transferred to Cipla for manufacture in Asia and to secure WHO prequalification in 2012. Incorporated into MMV portfolio in 2015
Project Director	Adam Aspinall

* ACPR = adequate clinical and parasitological response